

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 177 792 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**06.02.2002 Bulletin 2002/06**

(51) Int Cl.7: **A61K 31/505, A61P 25/30,  
A61P 25/32, A61P 43/00**

(21) Application number: **01306163.5**

(22) Date of filing: **18.07.2001**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **27.07.2000 US 221268 P**

(71) Applicant: **Pfizer Products Inc.  
Groton, Connecticut 06340 (US)**

(72) Inventors:  
• **Fliri, Anton Franz Josef  
Groton, Connecticut 06340 (US)**

• **Sanner, Mark Allen  
Groton, Connecticut 06340 (US)**  
• **Seymour, Patricia Ann  
Groton, Connecticut 06340 (US)**  
• **Zorn, Stevin Howard  
Groton, Connecticut 06340 (US)**

(74) Representative: **Ruddock, Keith Stephen et al  
Pfizer Limited, European Patent Department,  
Ramsgate Road  
Sandwich, Kent CT13 9NJ (GB)**

(54) **Dopamine D4 Ligands for the treatment of novelty-seeking disorders**

(57) The use of a dopamine D4 receptor ligand in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder, particularly pathological gambling, attention deficit disorder with hy-

peractivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

EP 1 177 792 A2

## Description

[0001] The present invention relates to a method of treating or preventing a novelty-seeking disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, such as drug addiction and alcohol addiction, and sex addiction, using a dopamine D4 ligand. It also relates to a method of treating or preventing such disorders in mammals by administering a pyrido[1,2a]pyrazine derivative, benzimidazole derivative, bicyclic compound, spirocyclic benzo furan derivative, indole derivative or a related compound that is a dopamine D4 receptor ligand.


[0002] It has been determined that dopamine D4 receptors are related to various behavioral and personality disorders including novelty seeking disorders (See, e.g., Tarazi et al., *Mol. Psychiatry*, 4, 529-538(1999)). The trait of novelty seeking was found to be related to dopaminergic activity in alcoholic men (Wiesbeck et al., *Psychoneuroendocrinology*, 20, 7(1999)). A large Finnish study provides support for an association between the D4 receptor gene (DRD4) and the behavioral trait of novelty seeking (Ekelund et al., *Am. J. Psychiatry*, 156, 1453-5 (1999)). Recent evidence has accumulated which supports a clinical linkage between attention deficit disorder with hyperactivity disorder, which has been associated with the novelty seeking trait, and dopamine receptor expression (see, e.g., Tarazi et al., *supra*; Anderson et al., *Neuroscience & Biobehavioral Rev.*, 24, 137-41 (2000)) and dopamine transporter gene expression (see, e.g., Dougherty et al., *The Lancet*, 354, 2132-2133 (1999)). Further evidence has been found for an association between the D4 gene and a susceptibility to pathological gambling (Comings, *CNS Spectr.*, 3, 20-37 (1998)) and a susceptibility to opioid addiction and substance abuse (Kotler et al., *Mol. Psychiatry*, 2, 251-254 (1997)).

[0003] The following references refer, collectively, to pyrido[1,2a]pyrazine derivatives, benzimidazole derivatives, bicyclic compounds, spirocyclic benzofuran derivatives, indole derivatives or related compounds that exhibit activity as dopamine D4 receptor ligands: United States Patent No. 5,852,031, issued on December 22, 1998; United States Patent No. 5,883,094, issued on March 16, 1999; United States Patent No. 5,889,010, issued on March 30, 1999; PCT International Application PCT/IB97/00978, published as WO98/08835 on March 5, 1998; United States Patent Application No. 5,877,317 issued on March 2, 1999; United States Patent Application No. 5,021,420, issued on June 4, 1991; United States Patent Application No. 5,633,376, issued on May 27, 1997; United States Patent Application, No. 5,432,177, issued on November 9, 1994; United States Patent Application No. 5,622,950, issued on April 22, 1997; PCT International Application No. PCT/EP93/01438, published as WO94/00458 on January 6, 1994; PCT International Application No. PCT/IB98/01198, published as WO99/09025 on February 25, 1999; United States Patent Application No. 5,998,414, issued on December 7, 1999; United States Patent Application No. 5,968,478, issued on October 19, 1999; United States Patent Application No. 6,040,448, issued on March 21, 2000; United States Patent Application No. 6,051,605, issued on April 18, 2000; United States Patent Application No. 5,945,421, issued on August 31, 1999; and United States Patent Application No. 5,798,350, issued on August 25, 1998. All of the foregoing PCT International Applications designate the United States. The foregoing patents and patent applications are incorporated by reference in their entirety.

## Summary of the Invention

[0004] This invention relates to a method of treating or preventing a novelty-seeking disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder (ADHD), substance addiction (e.g., drug addiction and alcohol addiction) and sex addiction in a subject, including a human, comprising administering to the subject an effective amount of:

(a) a compound of formula I:



wherein Ar is phenyl, naphthyl, benzoxazolonyl, indolyl, indolonyl, benzimidazolyl, quinolyl, furyl, benzofuryl, thienyl, benzothienyl, oxazolyl, or benzoxazolyl;


Ar<sup>1</sup> is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzisoxazolyl, or benzisothiazolyl; A is O, S, SO, SO<sub>2</sub>, C=O, CHO, or -(CR<sup>3</sup>R<sup>4</sup>)-; n is 0, 1 or 2; each of Ar and Ar<sup>1</sup> may be independently and optionally substituted with one to four substituents independently selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, nitro, thiocyno, -SR, -SOR, -SO<sub>2</sub>R, -NHSO<sub>2</sub>R, -(C<sub>1</sub>-C<sub>6</sub>)alkoxy, -NR<sup>1</sup>R<sup>2</sup>, -NRCOR<sup>1</sup>, -CONR<sup>1</sup>R<sup>2</sup>, Ph, -COR, COOR, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with one to six halogens, -(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and trifluoromethoxy;

each and every R, R<sup>1</sup>, and R<sup>2</sup> is independently selected from the group consisting of hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with one to thirteen halogens selected from fluorine, chlorine, bromine and iodine, phenyl, benzyl, -(C<sub>2</sub>-C<sub>6</sub>)alkenyl, -(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and -(C<sub>1</sub>-C<sub>6</sub>)alkoxy;

each and every R<sup>3</sup> and R<sup>4</sup> is independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, or i-propyl; diastereomeric and optical isomers thereof; and pharmaceutically acceptable salts thereof;

(b) a compound of formula II:

II:



wherein X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> are independently selected from carbon and nitrogen;


R<sup>0</sup>, R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms and (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms;

R<sup>3</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or benzyl, wherein the phenyl moiety of said benzyl group may optionally be substituted with from one or more substituents, preferably with from zero to three substituents, independently selected from halo (e.g., chloro, fluoro, bromo or iodo), cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, amino, di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino and (C<sub>1</sub>-C<sub>6</sub>)carboxamido;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (phenyl)[(C<sub>1</sub>-C<sub>6</sub>)acyl]amino, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino and di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino;

with the proviso that when X<sup>3</sup> is nitrogen, R<sup>2</sup> is absent;

(c) a compound of formula III:



(III)

wherein each of the dotted lines represents an optional double bond;

X is carbon or nitrogen;

R<sup>1</sup> is benzyl, aryl selected from phenyl, indanyl and naphthyl, or heteroaryl selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl, wherein each of the foregoing aryl, heteroaryl and (C<sub>1</sub>-C<sub>4</sub>)alkyl groups, and the phenyl moiety of the benzyl group, may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo (e.g., chloro, fluoro, bromo or iodo), (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, cyano, -C(=O)R<sup>8</sup>, aryl and heteroaryl, wherein said aryl is selected from phenyl, indanyl and naphthyl and said heteroaryl is selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl;

R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, cyano, -CONH<sub>2</sub> and -NHC(=O)R<sup>9</sup>, or R<sup>2</sup> and R<sup>3</sup> together form an oxo group;

R<sup>4</sup> is hydrogen, sulfur, oxygen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, amino, -NHR<sup>10</sup>, -SR<sup>10</sup>, OR<sup>10</sup> or hydroxy;


R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (phenyl)[(C<sub>1</sub>-C<sub>6</sub>)acyl]amino, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino, aryl and heteroaryl, wherein said aryl is selected from phenyl, naphthyl and indanyl, and said heteroaryl is selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl;

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are independently selected from hydrogen and (C<sub>1</sub>-C<sub>6</sub>)alkyl; and

R<sup>11</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or benzyl, wherein the phenyl moiety of said benzyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo (e.g., fluoro, chloro, bromo, or iodo), (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, amino, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkylamino and di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino;

with the proviso that: (a) R<sup>4</sup> can not be either oxygen or hydroxy when both R<sup>2</sup> and R<sup>3</sup> are hydrogen; (b) when the five membered ring of formula I contains a double bond, R<sup>11</sup> is absent; (c) when R<sup>4</sup> is sulfur or oxygen, R<sup>4</sup> is double bonded to the carbon to which is attached and such carbon is single bonded to both adjacent ring nitrogen atoms; and (d) when X is nitrogen and is double bonded to an adjacent carbon, R<sup>1</sup> is absent;

(d) a compound of formula IV:



and to pharmaceutically acceptable salts and solvates thereof wherein:

the dashed line in the above formula represents an optional double bond where X<sup>2</sup> is not O;

X<sup>1</sup> and X<sup>2</sup> are each independently selected from O and -(CH<sub>2</sub>)<sub>j</sub>- wherein j is 1 or 2;

X<sup>3</sup> is -CH(R<sup>5</sup>)N(R<sup>8</sup>)CH(R<sup>6</sup>)-, -CH(R<sup>5</sup>)C(R<sup>8</sup>)(R<sup>9</sup>)CH(R<sup>6</sup>)-, -C(R<sup>5</sup>)=C(R<sup>8</sup>)CH(R<sup>6</sup>)-, or -CH(R<sup>5</sup>)C(R<sup>8</sup>)=C(R<sup>6</sup>)-;

R<sup>1</sup> and R<sup>2</sup> are each independently H, hydroxy, or C<sub>1</sub>-C<sub>6</sub> alkyl;

or R<sup>1</sup> and R<sup>2</sup> are taken together as a bond;

each R<sup>3</sup> is independently selected from -S(O)<sub>j</sub>R<sup>7</sup> wherein j is an integer ranging from 0 to 2, -C(O)R<sup>7</sup>, -OR<sup>7</sup>, -NC(O)R<sup>7</sup>, -NR<sup>7</sup>R<sup>12</sup>, and the substituents provided in the definition of R<sup>7</sup> other than H;

R<sup>4</sup> is absent where the dashed line in the above formula 1 represents a double bond or R<sup>4</sup> is selected from H and the substituents provided in the definition of R<sup>3</sup>;

or R<sup>3</sup> and R<sup>4</sup> are taken together with the carbon atom to which each is attached to form a 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and -N(R<sup>11</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said cyclic group is saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo -C(O)- moiety;

and said cyclic group is optionally substituted by 1 to 3 R<sup>10</sup> groups;

R<sup>5</sup> and R<sup>6</sup> are each independently selected from H and C<sub>1</sub>-C<sub>4</sub> alkyl;

or R<sup>5</sup> and R<sup>6</sup> are taken together as -(CH<sub>2</sub>)<sub>q</sub>- wherein q is 2 or 3;

or R<sup>5</sup> or R<sup>6</sup> is taken together with R<sup>8</sup> as defined below;

each R<sup>7</sup> is independently selected from H, -(CH<sub>2</sub>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) and -(CH<sub>2</sub>)<sub>t</sub>(4-10 membered heterocyclic), wherein t is an integer ranging from 0 to 5; 1 or 2 of the carbon atoms of said heterocyclic group optionally may be replaced with an oxo -C(O)- group; said aryl and heterocyclic R<sup>7</sup> groups are optionally fused to a benzene ring, a C<sub>5</sub>-C<sub>8</sub> saturated cyclic group, or a 4-10 membered heterocyclic group; the -(CH<sub>2</sub>)<sub>t</sub>- moieties of the foregoing R<sup>7</sup> groups optionally include a carbon-carbon double or triple bond where t is an integer between 2 and 5; and the foregoing R<sup>7</sup> groups, except H, are optionally substituted by 1 to 5 R<sup>10</sup> groups;

R<sup>8</sup> is selected from the substituents provided in the definition of R<sup>7</sup> other than H;

R<sup>9</sup> is selected from the substituents provided in the definition of R<sup>7</sup>;


or R<sup>8</sup> and R<sup>9</sup> are taken together with the carbon to which each is attached to form a 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group is carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and -N(R<sup>11</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo -C(O)- moiety; and said cyclic group is optionally substituted by 1 to 3 R<sup>10</sup> groups;

or R<sup>8</sup> taken together with either R<sup>5</sup> or R<sup>6</sup> and the separate carbon atoms to which each is attached to form a fused 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and -N(R<sup>11</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo -C(O)- moiety; and said cyclic group is optionally substituted by 1 to 3 R<sup>10</sup> groups;

each R<sup>10</sup> is independently selected from C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -OR<sup>11</sup>, -C(O)R<sup>11</sup>, -C(O)OR<sup>11</sup>, -NR<sup>12</sup>C(O)OR<sup>11</sup>, -OC(O)R<sup>11</sup>, -NR<sup>12</sup>SO<sub>2</sub>R<sup>11</sup>, -SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, -NR<sup>12</sup>C(O)R<sup>11</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, -NR<sup>11</sup>R<sup>12</sup>, -S(O)<sub>j</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl) wherein j is an integer ranging from 0 to 2, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -SO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -S(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -O(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) and -(CH<sub>2</sub>)<sub>m</sub>(4-10 membered heterocyclic), wherein m is an integer ranging from 0 to 4; said

C<sub>1</sub>-C<sub>10</sub> alkyl group optionally contains 1 or 2 hetero moieties selected from O, S and -N(R<sup>12</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said aryl and heterocyclic R<sup>10</sup> groups are optionally fused to a C<sub>6</sub>-C<sub>10</sub> aryl group, a C<sub>5</sub>-C<sub>8</sub> saturated cyclic group, or a 4-10 membered heterocyclic group; and said alkyl, aryl and heterocyclic R<sup>10</sup> groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -NR<sup>12</sup>SO<sub>2</sub>R<sup>11</sup>, -SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, -C(O)R<sup>11</sup>, -C(O)OR<sup>11</sup>, -OC(O)R<sup>11</sup>, -NR<sup>12</sup>C(O)R<sup>11</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, -NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, -OR<sup>11</sup> and the substituents listed in the definition of R<sup>11</sup>; each R<sup>11</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(4-10 membered heterocyclic), wherein m is an integer ranging from 0 to 4; said alkyl group optionally includes 1 or 2 hetero moieties selected from O, S and -N(R<sup>12</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said aryl and heterocyclic R<sup>11</sup> groups are optionally fused to a C<sub>6</sub>-C<sub>10</sub> aryl group, a C<sub>5</sub>-C<sub>8</sub> saturated cyclic group, or a 4-10 membered heterocyclic group; and the foregoing R<sup>11</sup> substituents, except H, are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -C(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -CO(O)R<sup>12</sup>, -NR<sup>12</sup>C(O)R<sup>13</sup>, -C(O)NR<sup>12</sup>R<sup>13</sup>, -NR<sup>12</sup>R<sup>13</sup>, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy; and, each R<sup>12</sup> and R<sup>13</sup> is independently H or C<sub>1</sub>-C<sub>6</sub> alkyl;

(e) a compound of formula V:



or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

a is 0 or 1, wherein when a is 0, X may form an optional double bond with the carbon adjacent to V;

V is CHR<sup>10</sup> wherein R<sup>10</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

T is nitrogen or CH;

X is nitrogen or CR<sup>11</sup> wherein R<sup>11</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy or cyano;

Y and Z are each independently nitrogen or CR<sup>12</sup> wherein R<sup>12</sup> is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or (C<sub>1</sub>-C<sub>6</sub>)alkyl;


R<sup>1</sup> is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>2</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and

R<sup>5</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, trifluoromethyl, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl or R<sup>13</sup>CO- wherein R<sup>13</sup> is amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl;

or when a is 1, R<sup>1</sup> and R<sup>10</sup> may be taken together with the carbons to which they are attached to form a compound of the formula



wherein the broken lines represent optional bonds;

T, X, Y, Z, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> are defined as above;

b is 0 or 1; and


A and B are each independently CH, CH<sub>2</sub>, oxygen, sulfur, NH or nitrogen;

with the proviso that when X is nitrogen, the optional double bond between X and V does not exist;

with the proviso that when b is 0, the optional double bond between A and B does not exist; and

with the proviso that when b is 1, A and B cannot both be oxygen or sulfur;

or (f) a compound of formula VI:



(VI)

wherein a is oxygen, CH<sub>2</sub>, C(CH<sub>3</sub>)<sub>2</sub>, NR<sup>10</sup>, sulfur, SO or SO<sub>2</sub>;

b is oxygen, CH<sub>2</sub>, C=O, C=NR<sup>11</sup>, C=NOH, SO<sub>2</sub>, sulfur, SO, C=NO(C<sub>1</sub>-C<sub>5</sub>)alkyl or CR<sup>7</sup>R<sup>8</sup>;

each of R<sup>1</sup> through R<sup>8</sup> is selected, independently, from hydrogen, halogen (e.g., chloro, fluoro, bromo or iodo), trifluoromethyl, cyano and hydroxy, or R<sup>7</sup> and R<sup>8</sup> together can be C(=O)NH<sub>2</sub> or C(=O)N(C<sub>1</sub>-C<sub>4</sub>)alkyl, with the proviso that neither R<sup>7</sup> nor R<sup>8</sup> can be halo when a is oxygen, NR<sup>11</sup>, sulfur, SO or SO<sub>2</sub>; and

each of R<sup>10</sup> and R<sup>11</sup> is selected, independently, from hydrogen, benzyl and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

and the pharmaceutically acceptable salts of such compounds.

**[0005]** The term "one or more substituents", as used herein, includes from one to the maximum number of substituents possible based on the number of available bonding sites.

**[0006]** The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

**[0007]** The term "alkoxy", as used herein, unless otherwise indicated, refers to radicals having the formula -O-alkyl, wherein "alkyl" is defined as above.

**[0008]** In one embodiment this invention relates to a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of a compound of formula I wherein

**[0009]** Ar is phenyl, naphthyl, benzoxazolonyl, indolyl, indolonyl, benzimidazolyl, or quinolyl; Ar<sup>1</sup> is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or benzisoxazolyl; A is O, S, SO<sub>2</sub>, C=O, CHOH, or CH<sub>2</sub>; n is 0 or 1, wherein Ar and Ar<sup>1</sup> may be independently substituted with up to three substituents independently selected from the group consisting of fluoro, chloro, cyano, -NR<sup>1</sup>R<sup>2</sup>, -(C<sub>1</sub>-C<sub>6</sub>)alkoxy, -COOR, -CONR<sup>1</sup>R<sup>2</sup>, and -(C<sub>1</sub>-C<sub>6</sub>)alkyl and the pharmaceutically acceptable salts thereof.

**Embodiments of Formula I**

**[0010]** In certain embodiments, this invention relates to a method of treating or preventing a novelty-seeking, comprising administering to the subject an effective amount of a compound of formula I wherein A is O or S; n is 1; Ar is phenyl or substituted phenyl, and the pharmaceutically acceptable salts thereof.

**[0011]** In other embodiments, this invention relates to a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of a compound of formula I wherein A is CH<sub>2</sub>; n is 0; Ar is benzoxazolonyl or substituted benzoxazolonyl; and the pharmaceutically acceptable salts thereof.; or wherein A is CH<sub>2</sub>; n is 0; Ar is indolyl or substituted indolyl; and the pharmaceutically acceptable salts thereof; or wherein A is C=O or CHOH; n is 0 or 1; Ar is phenyl or substituted phenyl; and the pharmaceutically acceptable salt thereof; or wherein A is O; Ar is fluorophenyl, difluorophenyl or cyanophenyl; Ar<sup>1</sup> is chloropyridinyl; and the pharmaceutically acceptable salt thereof; or wherein A is O; Ar is fluorophenyl, difluorophenyl or cyanophenyl; Ar<sup>1</sup> is fluoropyrimidinyl; and the pharmaceutically acceptable salt thereof; or wherein A is O; Ar is fluorophenyl, difluorophenyl or cyanophenyl; Ar<sup>1</sup> is fluorophenyl; and the pharmaceutically acceptable salt thereof; or wherein Ar<sup>1</sup> is 5-chloro-pyridin-2-yl; and the pharmaceutically acceptable salt thereof; or wherein Ar<sup>1</sup> is 5-fluoro-pyrimidin-2-yl; and the pharmaceutically acceptable salts thereof.

**[0012]** In preferred embodiments of the method, A is O; S, SO, or SO<sub>2</sub>; C=O or CHOH; CH<sub>2</sub>; phenyl or substituted phenyl;

**[0013]** In other preferred embodiments of the method, Ar is naphthyl or substituted naphthyl; benzoxazolonyl or substituted benzoxazolonyl; indolyl or substituted indolyl; indolonyl or substituted indolonyl; benzimidazolyl or substituted benzimidazolyl; quinolyl or substituted quinolyl.

**[0014]** In other preferred embodiments of the method, Ar<sup>1</sup> is phenyl or substituted phenyl; pyridinyl or substituted pyridinyl; pyridazinyl or substituted pyridazinyl; pyrimidinyl or substituted pyrimidinyl; pyrazinyl or substituted pyrazinyl; benzisoxazolyl or substituted benzisoxazolyl.

**[0015]** Specific preferred embodiments of the invention relate to a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of the following compounds:

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(3,5-difluorophenoxy)methyl-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

3-[(7R,9aS)-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-ylmethyl]-3H-benzoxazol-2-one;

3-[(7R,9aS)-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-ylmethyl]-3H-benzoxazol-2-one;

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(3,5-difluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(3,4-difluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(3-cyanophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(4-cyanophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(4-iodophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(4-fluorophenyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(4-fluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(2-carbomethoxy-4-fluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(2-bromo-4-fluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(4-fluoro-2-trifluoromethylphenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(3,5-difluorophenoxy)methyl-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;



(7S,9aS)-7-(4-fluorophenoxy)methyl-2-(5-chloro-pyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(2-chlorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(4-fluoro-2-methylphenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7S,9aS)-7-(2,4-difluorophenoxy)methyl-2-(5-fluoro-pyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine; and the pharmaceutically acceptable salt thereof.

## Embodiments of Formula II

**[0016]** In preferred embodiments of the invention, compounds used in the practice of the invention include those of the formula II, wherein R<sup>1</sup> is bromine and X<sup>2</sup> is nitrogen; or wherein R<sup>1</sup> is chlorine and X<sup>2</sup> is nitrogen.

**[0017]** Examples of specific compounds based on formula II used in this invention include the following:

1-[3-(4-pyridin-2-yl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[3-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[3-[4-(5-chloro-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[3-[4-(5-bromo-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; and  
 1-[3-[4-(6-chloro-pyridazin-3-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one.

**[0018]** Other embodiments of this invention include methods using compounds of the formula II wherein X<sup>2</sup> is carbon, X<sup>3</sup> is nitrogen and R<sup>1</sup> is hydrogen or substituted or unsubstituted alkoxy; or wherein X<sup>2</sup> and X<sup>3</sup> are both carbon and R<sup>1</sup> is hydrogen or substituted or unsubstituted alkoxy; or wherein X<sup>1</sup> is carbon; or wherein X<sup>2</sup> and X<sup>3</sup> are both carbon and each of R<sup>0</sup>, R<sup>1</sup> and R<sup>2</sup> is other than a fluoroalkyl group; or wherein X<sup>1</sup> is nitrogen.

**[0019]** Other embodiments of this invention include use of the following compounds of formula II:

1-[2-cyano-3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[5-methyl-3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[6-cyano-3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[3-[4-(5-fluoro-pyridin-2-yl)-propyl]-3-methyl-1,3-dihydro-benzoimidazol-2-one;  
 1-[3-[4-(3-cyano-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[3-[4-(4-cyano-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[3-[4-(6-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;  
 1-[3-[4-(5-fluoro-pyridin-2-yl)-piperazin-1-yl]-propyl]-5-fluoro-1,3-dihydro-benzoimidazol-2-one; and  
 1-[3-[4-(5-fluoro-pyridin-2-yl)-piperazin-1-yl]-propyl]-5,6-difluoro-1,3-dihydro-benzoimidazol-2-one.

**[0020]** Preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds:

1-Benzoimidazol-1-yl-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-(5-Chloro-benzoimidazol-1-yl)-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-[3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl]-5-trifluoromethyl-1H-benzoimidazole;  
 1-[3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl]-1H-benzoimidazole;  
 1-[3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl]-3-methyl-1,3-dihydro-benzoimidazol-2-one;  
 1-Benzoimidazol-1-yl-3-(4-o-tolyl-piperazine-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-m-tolyl-piperazine-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-p-tolyl-piperazin-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(4-chloro-phenyl)-phenyl-methyl]-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(2-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(4-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-pyrimidin-2-yl-piperazin-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-naphthalen-1-yl-piperazin-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-benzyl-piperazin-1-yl)-propan-2-ol;

1-Benzoimidazol-1-yl-3-[4-(2-trifluoromethyl-benzyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(2-ethoxy-benzyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3-(3-trifluoromethyl-phenyl)-propyl)-piperazin-1-yl]-propan-2-ol; and  
 1-Benzoimidazol-1-yl-3-[4-(2-(3-trifluoromethyl-phenyl)-ethyl)-piperazin-1-yl]-propan-2-ol;

**[0021]** Other preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds of formula II:

(4-Chloro-2-nitro-phenyl)-{3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl}-amine;  
 {3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl}-(2-nitro-4-trifluoromethyl-phenyl)-amine;  
 4-Chloro-N1-{3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl}-benzene-1,2-diamine;  
 1-(4,5-Dichloro-2-nitro-phenylamino)-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-phenyl-benzoimidazol-1-yl)-propan-2-ol;  
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-propyl-benzoimidazol-1-yl)-propan-2-ol;  
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-methyl-benzoimidazol-1-yl)-propan-2-ol;  
 5-Fluoro-1-(3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl)-2-methyl-1H-benzoimidazole;  
 5-Chloro-1-(3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-2-hydroxy-propyl)-1,3-dihydro-benzoimidazol-2-one;  
 5-Fluoro-1-(3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-2-hydroxy-propyl)-1,3-dihydro-benzoimidazol-2-one;  
 1-Benzoimidazol-1-yl-3-[4-(3-methoxy-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(4-methoxy-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-phenyl-piperazin-1-yl)-propan-2-ol;  
 1-[4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-phenyl-ethanone;  
 1-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-3-benzoimidazol-1-yl-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3,4-dimethyl-phenyl)-piperazin-1-yl]-propan-2-ol;  
 4-[4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-phenol;  
 1-Benzoimidazol-1-yl-3-(4-phenethyl-piperazin-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3-phenyl-allyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3-chloro-propyl)-piperazin-1-yl]-propan-2-ol;  
 2-[4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-1-morpholin-4-yl-ethanone;  
 1-(4-Benzhydryl-piperazin-1-yl)-3-benzoimidazol-1-yl-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-bis-(4-fluoro-phenyl)-methyl]-piperazin-1-yl-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(4-nitro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazine-1-carboxylic;  
 5-Fluoro-1-(3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl)-1H-benzoimidazole;  
 3-[4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-1-phenyl-propan-1-one;  
 4-[4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one;  
 1-Benzoimidazol-1-yl-3-[4-(tetrahydro-furan-2-ylmethyl)-piperazin-1-yl]-propan-2-ol;  
 [4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-(tetrahydro-furan-2-yl)-methanone;  
 [4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-(2,3-dihydro-benzo[1,4]dioxin-2-yl)-methanone;  
 [4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-(tetrahydro-furan-2-yl)-methanone;  
 [[4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-2,3-dihydro-benzo[1,4]dioxin-2-yl]-methanone;  
 1-Benzoimidazol-1-yl-3-[4-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(2-nitro-butyl)-piperazin-1-yl]-propan-2-ol;  
 3-[4-(3-Benzoimidazol-1-yl-2-hydroxy-propyl)-piperazin-1-yl]-1-(4-chloro-phenyl)-propan-1-one;  
 1-Benzoimidazol-1-yl-3-[4-(5,5-diphenyl-pent-3-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-phenyl-benzoimidazol-1-yl)-propan-2-ol;  
 5,6-Difluoro-1-(3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl)-1H-benzoimidazole; and  
 1-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3-(2-propyl-benzoimidazol-1-yl)-propan-2-ol.

### **Embodiments of Formula III**

**[0022]** Other embodiments of this invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds:

- (a) compounds of formula III wherein R<sup>1</sup> is phenyl and is either unsubstituted or substituted with one or two substituents selected from halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy substituted with from one to three fluorine atoms, cyano, -C(=O)R<sup>8</sup>, aryl and heteroaryl;  
 (b) compounds of formula III wherein R<sup>1</sup> is indanyl and is either unsubstituted or substituted with one or two sub-

stituents selected from halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy substituted with from one to three fluorine atoms, cyano, -C(=O)R<sup>8</sup>, aryl and heteroaryl;

(c) compounds of formula III wherein R<sup>1</sup> is naphthyl and is either unsubstituted or substituted with one or two substituents selected from halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy substituted with from one to three fluorine atoms, cyano, -C(=O)R<sup>8</sup>, aryl and heteroaryl;

(d) compounds of formula III wherein R<sup>1</sup> is heteroaryl and is either unsubstituted or substituted with one or two substituents selected from halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy substituted with from one to three fluorine atoms, cyano, -C(=O)R<sup>8</sup>, aryl and heteroaryl;

(e) compounds of formula III wherein R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are independently selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, cyano and halo;

(f) compounds of formula III wherein R<sup>4</sup> is hydrogen;

(g) compounds of formula III wherein R<sup>4</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl;

(h) compounds of formula III wherein R<sup>4</sup> is amino;

(i) compounds of formula III wherein R<sup>4</sup> is -NHR<sup>10</sup>;

(j) compounds of formula III wherein R<sup>4</sup> is SR<sup>10</sup>;

(k) compounds of formula III wherein R<sup>4</sup> is -OR<sup>10</sup>;

(l) compounds of formula III wherein R<sup>4</sup> is hydroxy;

(m) compounds of formula III wherein R<sup>11</sup> is absent;

(n) compounds of formula III wherein R<sup>2</sup> and R<sup>3</sup> are both hydrogen;

(o) compounds of formula III wherein one or both of R<sup>2</sup> and R<sup>3</sup> are hydroxy;

(p) compounds of formula III wherein R<sup>2</sup> and R<sup>3</sup> together form an oxo group;

(q) compounds of formula III wherein one of R<sup>2</sup> and R<sup>3</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl;

(r) compounds of formula III wherein X is carbon;


(s) compounds of formula III wherein X is nitrogen;

(t) compounds of formula III wherein R<sup>4</sup> is oxygen; and


(v) compounds of formula III wherein R<sup>4</sup> is sulfur.

#### Embodiments of Formula IV


[0023] Certain embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of compounds of formula IV having the following structure



wherein R<sup>3</sup> is -(CH<sub>2</sub>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) or -(CH<sub>2</sub>)<sub>t</sub>(4-10 membered heterocyclic), R<sup>4</sup> is H or hydroxy, and R<sup>8</sup> is -(CH<sub>2</sub>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) or -(CH<sub>2</sub>)<sub>t</sub>(4-10 membered heterocyclic), t is an integer ranging from 0 to 5, and the foregoing R<sup>3</sup> and R<sup>8</sup> heterocyclic groups are optionally fused to a benzene ring, and said R<sup>3</sup> and R<sup>8</sup> groups are optionally substituted by 1 to 3 R<sup>10</sup> groups. More specific embodiments include use of those compounds wherein R<sup>8</sup> and R<sup>3</sup> are each independently selected from phenyl and pyrimidyl, optionally substituted by 1 to 3 substituents independently selected from halo, cyano, methoxy, trifluoromethyl, methanesulfonyl, amino, trifluoromethoxy, acetamido, and C<sub>1</sub>-C<sub>6</sub> alkyl. Other more specific embodiments include those wherein R<sup>3</sup> is a heterocyclic group fused to a benzene ring and, optionally, 1 or 2 of the carbon atoms of said heterocyclic group is replaced with an oxo -C(O)- group. In particular, such specific embodiments of the invention use compounds wherein R<sup>3</sup> comprises the following groups:




and




wherein the benzo portion of the above R<sup>3</sup> groups is optionally substituted by 1 to 3 R<sup>10</sup> groups.

**[0024]** Other embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any compound of formula IV having the following structure




wherein R<sup>3</sup> is -O(CH<sub>2</sub>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) or -O(CH<sub>2</sub>)<sub>t</sub>(4-10 membered heterocyclic), R<sup>4</sup> is H or hydroxy, and R<sup>8</sup> is -(CH<sub>2</sub>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) or -(CH<sub>2</sub>)<sub>t</sub>(4-10 membered heterocyclic), wherein t is an integer ranging from 0 to 5, and wherein the foregoing R<sup>3</sup> and R<sup>8</sup> groups are optionally substituted by 1 to 3 R<sup>10</sup> groups. More specific embodiments of the invention include the described method wherein R<sup>3</sup> is phenoxy and R<sup>8</sup> is phenyl or pyrimidyl, and said R<sup>3</sup> and R<sup>8</sup> groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, methoxy, trifluoromethyl, methanesulfonyl, amino, trifluoromethoxy, acetamido, and C<sub>1</sub>-C<sub>6</sub> alkyl.

**[0025]** Other embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any compound of formula IV having the following structure



wherein R<sup>3</sup> and R<sup>4</sup> are taken together with the carbon atom to which each is attached to form a 5-10 membered monocyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and -N(R<sup>11</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said cyclic group is saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo -C(O)- moiety; and said cyclic group is optionally substituted by 1 to 3 R<sup>10</sup> groups; and R<sup>8</sup> is -(CH<sub>2</sub>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) or -(CH<sub>2</sub>)<sub>t</sub>(4-10 membered heterocyclic), wherein t is an integer ranging from 0 to 5 and said R<sup>8</sup> group is optionally substituted by 1 to 3 R<sup>10</sup> groups. More specific embodiments of the invention include the described method wherein R<sup>8</sup> is phenyl or pyrimidyl, and R<sup>3</sup> and R<sup>4</sup> are taken together to form a group selected from



and said R<sup>8</sup>, R<sup>3</sup> and R<sup>4</sup> groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, methoxy, trifluoromethyl, methanesulfonyl, amino, trifluoromethoxy, acetamido, and C<sub>1</sub>-C<sub>6</sub> alkyl.

**[0026]** Specific embodiments of the invention include a method of treating or preventing a novelty-seeking, comprising administering to the subject an effective amount of any of the following compounds of formula IV:

- (2'α,3'aβ,5'α,6'aβ)-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-hexahydropentalene-2'-one;
- (2'α,3'aβ,5'α,6'aβ)-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2'-phenyl-octahydro-pentalen-2'ol, maleate salt;
- (2'α,3'aβ,5'α,6'aβ)-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-hexahydropentalene-2-one, ethylene ketal;
- (2'α,3'aβ,5'α,6'aβ)-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-hexahydropentalene-2-one;
- (2'α,3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(5'-hydroxy-5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate salt;
- (2α,3aβ,5α,6aβ)-5-Hydroxy-5-phenyl-hexahydro-pentalen-2-one;
- (2'α,3'aβ,5'α,6'aβ)-5'-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-2'-phenyl-octahydro-pentalen-2'ol, maleate salt;
- (2'α,3'aβ,5'α,6'aβ)-5'-[4-(4-Fluoro-1-pyrimidyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'ol, maleate salt;
- (2'α,3'aβ,5'α,6'aβ)-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'ol, maleate salt;
- (2'α,3'aβ,5'α,6'aβ)-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'ol, maleate salt;
- (2'α, 3'aβ, 6'aβ)-1-(4-Fluoro-phenyl)-4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazine dihydrochloride;
- (2'α, 3'aβ, 6'aβ)-5-Fluoro-2-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine maleate;
- (2'α,3'aβ,6'aβ)-2-Fluoro-4-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;
- (2'α, 3'aβ, 6'aβ)-2-Fluoro-4-[4-[5-(2-methoxy-phenyl)-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;
- (2'α, 3'aβ, 6'aβ)-1-Phenyl-4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazine, dimaleate;
- (2'α, 3'aβ, 5'α, 6'aβ)-1-(4-Fluoro-phenyl)-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine, dihydrochloride;
- (2'α, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;
- (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;
- (2'α, 3'aβ, 5'α, 6'aβ)-1-Phenyl-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine, maleate;
- (2'α,3'aβ,5'α,6'aβ)-5'-Hydroxy-5'-(2-trifluoromethyl-phenyl)-hexahydro-pentalen-2'-one;
- (2'α,3'aβ,6'aβ)-5'-(2-trifluoromethyl-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2'-one, ethylene ketal;
- (2'α,3'aβ,5'α,6'aβ)-5'-(2-Trifluoromethyl-phenyl)-hexahydro-1H-pentalen-2'-one, ethylene ketal;
- (2'α,3'aβ,5'α,6'aβ)-5'-(2-Trifluoromethyl-phenyl)-hexahydro-1H-pentalen-2'-one;
- (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-[5'-(2-trifluoromethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;
- (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;
- (2'α, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-[4[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-pyrimidine, maleate;
- (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4[5'-(3-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;
- (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4[5'-(4-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;

- (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-5-Chloro-2-[4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-pyrimidine, maleate;  
 5 (2'α, 3'aβ, 5'α, 6'aβ)-5-Chloro-2-[4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-[5'-(2-methanesulfonyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-1-Phenyl-4-[5'-(3-pyrrolidin-1-ylmethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazine, di-maleate;  
 10 5-Trimethylstannayl-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, ethylene ketal;  
 5-(2-Cyano-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Cyano-4-[4-[5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-[5'-(2-trifluoromethoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;  
 15 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-[5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(5'-pyridin-2-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile, dihydrochloride;  
 20 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(5'-m-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(5'-p-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-N-(2-[5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-phenyl)-acetamide, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-N-(2-[5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-phenyl)-acetamide, maleate;  
 25 5-(2-Cyano-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, ethylene ketal;  
 2-(5-Oxo-octahydro-pentalen-2-yl)-benzamide, ethylene ketal;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-[5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-benzamide, maleate;  
 30 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-2-Fluoro-4-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzo-nitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-piperazin-1-yl]-pyrimidine;  
 35 (2'β, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-piperazin-1-yl]-pyrimidine;  
 (2'α, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydro-3'a,6'a-dimethylspiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine, maleate;  
 40 (2'β, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-[4-(3', 3'a, 4', 5', 6', 6'a-hexahydro-3'a,6'a-dimethylspiro[isobenzofuran-1(3H), 2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(3', 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-2-Fluoro-4-[4-(3', 3', 3'a, 4, 4', 5', 6', 6'a-hexa-hydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 45 (2'α, 3'aβ, 5'α, 6'aβ)-1-Phenyl-4-(3', 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-5'-yl]-piperazine, maleate;  
 (2'β, 3'aβ, 5'α, 6'aβ)-1-Phenyl-4-(3', 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-5'-yl]-piperazine, maleate;  
 50 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(3', 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 (2'β, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(3', 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 (2α,3aβ,5α,6aβ)-5-Benzylamino-hexahdropentalen-2-one, mono -ethylene ketal;  
 55 (2α,3aβ,5α,6aβ)-5-Amino-hexahdropentalen-2-one, mono-ethylene ketal;  
 (2α,3aβ,5α,6aβ)-5-(5-Fluoro-2-nitro-phenylamino)-hexahdropentalen-2-one, mono - ethylene ketal;  
 (2α,3aβ,5α,6aβ)-5-(2-Amino-5-fluoro-phenylamino)-hexahdropentalen-2-one, mono - ethylene ketal;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-[5'-(6-fluoro-2-oxo-2,3-dihydro-benzimidazol-1-yl)-octahydro-pentalen-2'-yl]-

piperazin-1-yl)-benzonitrile, dimesylate;

(2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, mesylate;

(2'α, 3'aβ, 5'α, 6'aβ)-1-[5'-(4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1,3-dihydro-benzoimidazol-2-one, mesylate;

(2α,3aβ,5α,6aβ)-5-(6-Fluoro-2-methyl-benzoimidazol-1-yl)-hexahydro-pentalen-2-one;

(2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(6-fluoro-2-methylbenzoimidazol-1-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, dimesylate;

(2'α, 3'aβ, 5'α, 6'aβ)-6-Fluoro-2-methyl-1-[5'-(4-phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-benzoimidazole, dimaleate;

(2α,3aβ,6aβ)-5-(1H-Indol-3-yl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, mono-ethylene ketal;

(2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(1H-indol-3-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

(2'α, 3'aβ, 5'α, 6'aβ)-3-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-indole, maleate;

(2α,3aβ,6aβ)-5-(4-Fluoro-phenoxy)-hexahydro-pentalen-2-one;

(2'α, 3'aβ, 5'β, 6'aβ)-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine, maleate;

(2'α, 3'aβ, 5'β, 6'aβ)-2-Fluoro-4-{4-[5'-(4-fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

(2'α, 3'aβ, 5'β, 6'aβ)-5-Fluoro-2-{4-[5'-(4-fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-pyrimidine, maleate;

(2'β, 3'aβ, 5'β, 6'aβ)-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine, maleate;

(2'α, 3'aβ, 5'β, 6'aβ)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione maleate;

(2'α,3'aβ,5'α,6'aβ)-5-Hydroxy-hexahydro-pentalen-2-one, ethylene ketal;

(2'α,3'aβ,5'α,6'aβ)-2-Oxo-3-(5-oxo-octahydro-pentalen-2-yl)-2,3-dihydro-benzoimidazole-1-carboxylic acid tert-butyl ester, ethylene ketal;

(2'α,3'aβ,5'α,6'aβ)-2-(5-oxo-octahydro-pentalen-2-yloxy)-3H-benzoimidazole-1-carboxylic acid tert-butyl ester, ethylene ketal;

(2'β, 3'aβ, 5'α, 6'aβ)-3-[5'-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid tert-butyl ester;

(2'β, 3'aβ, 5'α, 6'aβ)-1-[5'-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1,3-dihydro-benzoimidazol-2-one, maleate;

(2'α, 3'aβ, 5'β, 6'aβ)-2-Fluoro-4-{4-[5'-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;

(2'β, 3'aβ, 5'α, 6'aβ)-1-[5'-(4-(3,4-Difluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1,3-dihydro-benzoimidazol-2-one, maleate;

(2'β, 3'aβ, 5'α, 6'aβ)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yloxy]-1H-benzoimidazole, maleate;

(2'α,3'aβ,5'α,6'aβ)-2-(5-Oxo-octahydro-pentalen-2-yl)-isoindole-1,3-dione;

(2'α, 3'aβ, 5'β, 6'aβ)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione, maleate;

(2'α, 3'aβ, 5'β, 6'aβ)-4-{4-[5'-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-2-fluoro-benzonitrile, maleate;

(2'α, 3'aβ, 5'β, 6'aβ)-2-[5'-(4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione, maleate;

(2'β, 3'aβ, 5'α, 6'aβ)-2-[5'-(4-(3,4-Difluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione, maleate;

(2'β, 3'aβ, 5'α, 6'aβ)-2-[5'-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione, maleate; and,

(2'β, 3'aβ, 5'α, 6'aβ)-N-[5-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2-yl]-benzamide, maleate.

### Embodiments of Formula V

[0027] Preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of the compound of formula V wherein X is nitrogen; or wherein Y and Z are each CR<sup>12</sup> wherein R<sup>12</sup> is hydrogen or fluoro; or wherein R<sup>2</sup> is hydrogen, fluoro or chloro; or wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen; or wherein R<sup>7</sup> is fluoro or chloro; or wherein R<sup>9</sup> is fluoro, chloro, bromo or alkoxy; or, more specifically, wherein X is nitrogen; Y and Z are each CR<sup>13</sup> wherein R<sup>13</sup> is hydrogen or fluoro; R<sup>2</sup> is hydrogen fluoro or chloro; R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen; R<sup>7</sup> is fluoro or chloro; and R<sup>9</sup> is fluoro, chloro, bromo or alkoxy.

[0028] Specific preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds of formula V:

2-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;  
 5-Fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;  
 5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;  
 5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;  
 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;  
 2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole;  
 5-Fluoro-2-(4-[5'-fluoro]pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;  
 2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole;  
 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole; and  
 2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-azaindole.

### Embodiments of Formula VI

**[0029]** Preferred embodiments of the invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the compounds of formula VI wherein a is oxygen, b is CH<sub>2</sub>, each of R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup> is hydrogen, and each of R<sup>2</sup>, R<sup>3</sup> and R<sup>6</sup> is selected, independently from hydrogen, cyano, chloro and fluoro.

**[0030]** Other more specific embodiments of this invention include a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the following compounds:

- (a) compounds of formula VI wherein a is oxygen;
- (b) compounds of formula VI wherein a is oxygen and b is CH<sub>2</sub>;
- (c) compounds of formula VI wherein a is oxygen, b is CH<sub>2</sub> and each of R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup> is hydrogen;
- (d) compounds of formula VI wherein a is oxygen, b is CH<sub>2</sub>, each of R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup> is hydrogen and R<sup>3</sup> is fluoro, cyano or chloro;
- (e) compounds of formula VI wherein a is oxygen, b is CH<sub>2</sub>, each of R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup> is hydrogen and each of R<sup>2</sup>, R<sup>3</sup> and R<sup>6</sup> is selected, independently, from hydrogen, fluoro, cyano and chloro; and
- (f) compounds of formula VI wherein a is oxygen, b is CH<sub>2</sub>, each of R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup> is hydrogen, and R<sup>2</sup> and R<sup>3</sup> are selected, independently, from fluoro, cyano and chloro.

**[0031]** The compounds of formula I, II, III, IV, V and VI above may contain chiral centers and therefore may exist in different enantiomeric forms. This invention relates to a method of treating or preventing a novelty-seeking disorder, comprising administering to the subject an effective amount of any of the optical isomers and all other stereoisomers of compounds of the formula I, II, III, IV, V and VI and mixtures thereof.

**[0032]** The compounds of formula I, II, III, IV, V and VI that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

**[0033]** Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I, II, III, IV, V and VI from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the basic compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.

**[0034]** The novel compounds of the formula I, II, III, IV, V and VI and the pharmaceutically acceptable salts thereof (herein referred to as "the therapeutic compounds of this invention") are useful as dopamine D<sub>4</sub> receptor ligands, i.e., they possess the ability to inhibit the binding of dopamine D<sub>4</sub> ligands to the dopamine D<sub>4</sub> receptor in various subjects, including humans. They and other dopamine D<sub>4</sub> receptor ligands are therefore able to function as therapeutic agents in the treatment or prevention of a variety of conditions in subjects, including humans, the treatment or prevention of which can be effected or facilitated by a decrease in binding of dopamine D<sub>4</sub> receptor ligands with the dopamine D<sub>4</sub> receptor, including a novelty-seeking disorder selected from pathological gambling, attention deficit disorder with hy-



peractivity disorder (ADHD), substance addiction (e.g., drug addiction and alcohol addiction) and sex addiction.

**[0035]** The term "dopaminergic effective amount", as used herein, refers to an amount sufficient to inhibit the binding of dopamine to a dopamine receptor.

**[0036]** The term "altering dopamine mediated neurotransmission", as used herein, includes but is not limited to increasing or decreasing D4 dopamine receptor mediated neurotransmission.

**[0037]** The term "novelty seeking disorder", as used herein, refers to a maladaptive variant of the personality trait of seeking novelty in the dimensional model of personality disorders. See DSM-IV. Examples of novelty-seeking disorders include: pathological gambling, attention deficit disorder with hyperactivity disorder (ADHD), substance addiction (e.g., drug addiction and alcohol addiction) and sex addiction.

### Detailed Description of the Invention

**[0038]** The compounds of the formula I, II, III, IV, V and VI may be prepared as described below. Unless otherwise indicated in the discussion that follows, structural formulae I, II, III, IV and V are defined as above.

**[0039]** Compounds of the formula I may be prepared as described in United States Patent No. 5,852,031, issued December 22, 1998. This patent is incorporated herein by reference in its entirety.

**[0040]** Compounds of the formula II may be prepared as described in United States Patent No. 5,883,094, issued March 16, 1999. This patent is incorporated herein by reference in its entirety.

**[0041]** Compounds of the formula III may be prepared as described in United States Patent No. 5,889,010, issued March 30, 1999. This patent is incorporated herein by reference in its entirety.

**[0042]** Compounds of the formula IV may be prepared as described in United States Patent Application No. 09/300,262, filed April 27, 1999. This application is incorporated herein by reference in its entirety.

**[0043]** Compounds of the formula V may be prepared as described in PCT International Application No. PCT/IB98/01198 and designates the United States, and was published as Publication No. published as WO99/09025 on February 25, 1999. This application is incorporated herein by reference in its entirety.

**[0044]** Compounds of the formula VI may be prepared as described in PCT International Application No. PCT/IB97/00978, which was filed in the International Bureau on August 8, 1997 and designates the United States, and was published as Publication No. WO98/08835 on March 5, 1998. This application is incorporated herein by reference in its entirety.

**[0045]** The compounds of the formula I, II, III, IV, V and VI, herein referenced to collectively as the "therapeutic agents" and the pharmaceutically acceptable salts thereof, are useful as dopamine D4 receptor ligands. Other dopamine D4 receptor ligands that may be used in accordance with the methods of this invention are the compounds and pharmaceutically acceptable salts thereof described in the following references: United States Patent Application No. 5,877,317 issued on March 2, 1999; United States Patent Application No. 5,021,420, issued on June 4, 1991; United States Patent Application No. 5,633,376, issued on May 27, 1997; United States Patent Application, No. 5,432,177, issued on November 9, 1994; United States Patent Application No. 5,622,950, issued on April 22, 1997; PCT International Application No. PCT/EP93/01438, published as WO94/00458 on January 6, 1994; United States Patent Application No. 5,998,414, issued on December 7, 1999; United States Patent Application No. 5,968,478, issued on October 19, 1999; United States Patent Application No. 6,040,448, issued on March 21, 2000; United States Patent Application No. 6,051,605, issued on April 18, 2000; United States Patent Application No. 5,945,421, issued on August 31, 1999; and United States Patent Application No. 5,798,350, issued on August 25, 1998. Each of the foregoing patents and patent publications is incorporated herein by reference in its entirety.

**[0046]** The therapeutic compounds used in this invention can be administered orally, transdermally (e.g., through the use of a patch), parenterally or topically. Oral administration is preferred. In general, these compounds are most desirably administered in dosages ranging from about 0.1 mg up to about 1000 mg per day, or 1 mg to 1000 mg per day in some cases, although variations may occur depending on the weight and condition of the person being treated and the particular route of administration chosen. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

**[0047]** The therapeutic compounds used in the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the two routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the novel therapeutic compounds of this invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, for example. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored.

[0048] For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

[0049] For parenteral administration, solutions of a therapeutic compound used in the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intra-articular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

[0050] Additionally, it is also possible to administer the compounds used in the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

[0051] Dopaminergic activity of the compounds used in the invention is related to the ability of the compounds to bind to the D<sub>4</sub> receptors, and the relative ability of compounds of this invention to inhibit [<sup>3</sup>H]-spiperone binding to human dopamine D<sub>4</sub> receptor subtypes expressed in clonal cell lines was measured using the following procedure.


[0052] The determination of D<sub>4</sub> receptor binding ability has been described by Van Tol et al., *Nature*, 350, 610 (1991)). Clonal cell lines expressing the human dopamine D<sub>4</sub> receptor are harvested and homogenized (polytron) in a 50 mM Tris:HCl (pH 7.4 at 4°C) buffer containing 5 mM EDTA, 1.5 mM calcium chloride (CaCl<sub>2</sub>), 5 mM magnesium chloride (MgCl<sub>2</sub>), 5mM potassium chloride (KCl) and 120 mM sodium chloride (NaCl). The homogenates are centrifugated for 10-15 min. at 48,000 g, and the resulting pellets resuspended in a buffer at a concentration of 150-250 mg/ml. For saturation experiments, 0.75 ml aliquots of tissue homogenate are incubated in triplicate with increasing concentrations of [<sup>3</sup>H] spiperone (70.3 Ci/mmol; 10-3000 pM final concentration) for 30-120 minutes at 22°C in a total volume of 1 ml. For competition binding experiments, assays are initiated by the addition of 0.75 ml of membrane and incubated in duplicate with the indicated concentrations of competing ligands (10<sup>-14</sup>-10<sup>-3</sup> M) and/or [<sup>3</sup>H]spiperone (100-300 pM) for 60-120 min at 22°C. Assays are terminated by rapid filtration through a Brandell cell harvester and the filters subsequently monitored for tritium as described by Sunahara, R.K. et al., *Nature*, 346, 76-80 (1990). For all experiments, specific [<sup>3</sup>H]spiperone binding is defined as that inhibited by 1-10 mM (+)-butaclamol. Binding data are analyzed by non-linear least squares curve-fitting. All of the compounds recited herein which were tested in this assay were found to have binding affinities (K<sub>i</sub>) for the displacement of [<sup>3</sup>H]-spiperone of less than 2 micromolar.

[0053] Utility of the present invention may be determined for the recited dopamine D<sub>4</sub> ligands by administering any of the ligands to subjects deemed to be suffering from a novelty-seeking disorder as determined from a Temperament and Character Inventory (Cloninger et al, *Arch. Gen. Psychiatry*, 50, 975-990 (1993)) and comparing the Novelty Seeking scores prior to and after the administration of the ligand. (See Malhotra et al., *Mol. Psychiatry*, 1, 388-391 (1996)). An improved Novelty Seeking score indicates an effective ligand dosage for administration to a subject in need of treatment.

## Claims

### 1. The use of:

(a) a compound of the formula



wherein Ar is phenyl, naphthyl, benzoxazolonyl, indolyl, indolonyl, benzimidazolyl, quinolyl, furyl, benzofuryl, thienyl, benzothienyl, oxazolyl, benzoxazolyl;

Ar<sup>1</sup> is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzisoxazolyl, or benzisothiazolyl;

A is O, S, SO, SO<sub>2</sub>, C=O, CHOH, or -(CR<sup>3</sup>R<sup>4</sup>)-;


n is 0, 1 or 2;

each of Ar and Ar<sup>1</sup> may be independently and optionally substituted with one to four substituents independently selected from the groups consisting of fluoro, chloro, bromo, iodo, cyano, nitro, thiocyno, -SR, -SOR, -SO<sub>2</sub>R, -NHSO<sub>2</sub>R, -(C<sub>1</sub>-C<sub>6</sub>)alkoxy, -NR<sup>1</sup>R<sup>2</sup>, -NRCOR<sup>1</sup>, -CONR<sup>1</sup>R<sup>2</sup>, Ph, -COR, COOR, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with one to six halogens, -(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and trifluoromethoxy;

each and every R, R<sub>1</sub>, and R<sub>2</sub> is independently selected from the group consisting of hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with one to thirteen halogens selected from fluorine, chlorine, bromine and iodine, phenyl, benzyl, -(C<sub>2</sub>-C<sub>6</sub>)alkenyl, -(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and -(C<sub>1</sub>-C<sub>6</sub>)alkoxy;

each and every R<sup>3</sup> and R<sup>4</sup> is independently selected from a group consisting of hydrogen, methyl, ethyl, n-propyl, and i-propyl;

or a diastereomeric or optical isomer thereof; or a pharmaceutically acceptable salt thereof; or  
(b) a compound of the formula



wherein X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> are independently selected from carbon and nitrogen;

R<sup>0</sup>, R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms and (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms;


R<sup>3</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or benzyl, wherein the phenyl moiety of said benzyl group may optionally be substituted with from one or more substituents, independently selected from halo, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, amino, di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino and (C<sub>1</sub>-C<sub>6</sub>)carboxamido;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo and iodo), cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (phenyl)[(C<sub>1</sub>-C<sub>6</sub>)acyl]amino, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino and di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino;

with the proviso that when X<sup>3</sup> is nitrogen, R<sup>2</sup> is absent;

or a pharmaceutically acceptable salt thereof; or

(c) a compound of the formula



wherein each of the dotted lines represents an optional double bond;

X is carbon or nitrogen;

R<sup>1</sup> is benzyl, aryl selected from phenyl, indanyl and naphthyl, or heteroaryl selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl, wherein each of the foregoing aryl, heteroaryl and (C<sub>1</sub>-C<sub>4</sub>)alkyl groups, and the phenyl moiety of the benzyl group, may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo (e.g., chloro, fluoro, bromo or iodo), (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, cyano, -C(=O)R<sup>8</sup>, aryl and heteroaryl, wherein said aryl is selected from phenyl, indanyl and naphthyl and said heteroaryl is selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl;

R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, cyano, -CONH<sub>2</sub> and -NHC(=O)R<sup>9</sup>, or R<sup>2</sup> and R<sup>3</sup> together form an oxo group;

R<sup>4</sup> is hydrogen, sulfur, oxygen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, amino, -NHR<sup>10</sup>, -SR<sup>10</sup>, OR<sup>10</sup> or hydroxy;


R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (phenyl)[(C<sub>1</sub>-C<sub>6</sub>)acyl] amino, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino, aryl and heteroaryl, wherein said aryl is selected from phenyl, naphthyl and indanyl, and said heteroaryl is selected from pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolyl and imidazolyl;

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are independently selected from hydrogen and (C<sub>1</sub>-C<sub>6</sub>)alkyl; and

R<sup>11</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or benzyl, wherein the phenyl moiety of said benzyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo (e.g., fluoro, chloro, bromo, or iodo), (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with from one to three fluorine atoms, amino, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkylamino and di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino;

with the proviso that: (a) R<sup>4</sup> can not be either oxygen or hydroxy when both R<sup>2</sup> and R<sup>3</sup> are hydrogen; (b) when the five membered ring of formula I contains a double bond, R<sup>11</sup> is absent; (c) when R<sup>4</sup> is sulfur or oxygen, R<sup>4</sup> is double bonded to the carbon to which is attached and such carbon is single bonded to both adjacent ring nitrogen atoms; and (d) when X is nitrogen and is double bonded to an adjacent carbon, R<sup>1</sup> is absent.

or a pharmaceutically acceptable salt thereof; or  
(d) a compound of the formula



or a pharmaceutically acceptable salt or solvate thereof wherein:

the dashed line in the above formula represents an optional double bond where X<sup>2</sup> is not O;

X<sup>1</sup> and X<sup>2</sup> are each independently selected from O and -(CH<sub>2</sub>)<sub>j</sub>- wherein j is 1 or 2;

X<sup>3</sup> is -CH(R<sup>5</sup>)N(R<sup>8</sup>)CH(R<sup>6</sup>)-, -CH(R<sup>5</sup>)C(R<sup>8</sup>)(R<sup>9</sup>)CH(R<sup>6</sup>)-, -C(R<sup>5</sup>)=C(R<sup>8</sup>)CH(R<sup>6</sup>)-, or -CH(R<sup>5</sup>)C(R<sup>8</sup>)=C(R<sup>6</sup>)-;

R<sup>1</sup> and R<sup>2</sup> are each independently H, hydroxy, or C<sub>1</sub>-C<sub>6</sub> alkyl; or R<sup>1</sup> and R<sup>2</sup> are taken together as a bond; each R<sup>3</sup> is independently selected from -S(O)<sub>j</sub>R<sup>7</sup> wherein j is an integer ranging from 0 to 2, -C(O)R<sup>7</sup>, -OR<sup>7</sup>, -NC(O)R<sup>7</sup>, -NR<sup>7</sup>R<sup>12</sup>, and the substituents provided in the definition of R<sup>7</sup> other than H;

R<sup>4</sup> is absent where the dashed line in the above formula represents a double bond or R<sup>4</sup> is selected from H and the substituents provided in the definition of R<sup>3</sup>; or R<sup>3</sup> and R<sup>4</sup> are taken together with the carbon atom to which each is attached to form a 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and -N(R<sup>11</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said cyclic group is saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo -C(O)- moiety; and said cyclic group is optionally substituted by 1 to 3 R<sup>10</sup> groups;

R<sup>5</sup> and R<sup>6</sup> are each independently selected from H and C<sub>1</sub>-C<sub>4</sub> alkyl; or R<sup>5</sup> and R<sup>6</sup> are taken together as -(CH<sub>2</sub>)<sub>q</sub>- wherein q is 2 or 3; or R<sup>5</sup> or R<sup>6</sup> is taken together with R<sup>8</sup> as defined below;

each R<sup>7</sup> is independently selected from H, -(CH<sub>2</sub>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) and -(CH<sub>2</sub>)<sub>t</sub>(4-10 membered heterocyclic), wherein t is an integer ranging from 0 to 5; 1 or 2 of the carbon atoms of said heterocyclic group optionally may be replaced with an oxo -C(O)- group; said aryl and heterocyclic R<sup>7</sup> groups are optionally fused to a benzene ring, a C<sub>5</sub>-C<sub>8</sub> saturated cyclic group, or a 4-10 membered heterocyclic group; the -(CH<sub>2</sub>)<sub>t</sub>- moieties of the foregoing R<sup>7</sup> groups optionally include a carbon-carbon double or triple bond where t is an integer between 2 and 5; and the foregoing R<sup>7</sup> groups, except H, are optionally substituted by 1 to 5 R<sup>10</sup> groups;


R<sup>8</sup> is selected from the substituents provided in the definition of R<sup>7</sup> other than H;

R<sup>9</sup> is selected from the substituents provided in the definition of R<sup>7</sup>; or R<sup>8</sup> and R<sup>9</sup> are taken together with the carbon to which each is attached to form a 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group is carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and -N(R<sup>11</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo -C(O)- moiety; and said cyclic group is optionally substituted by 1 to 3 R<sup>10</sup> groups; or R<sup>8</sup> taken together with either R<sup>5</sup> or R<sup>6</sup> and the separate carbon atoms to which each is attached to form a fused 5-10 membered mono-cyclic or bicyclic group wherein said cyclic group may be carbocyclic or heterocyclic with 1 to 3 heteroatoms selected from O, S, and -N(R<sup>11</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; saturated or partially unsaturated; aromatic or non-aromatic; 1 or 2 of the carbon atoms in said cyclic group optionally may be replaced by an oxo -C(O)-moiety; and said cyclic group is optionally substituted by 1 to 3 R<sup>10</sup> groups;

each R<sup>10</sup> is independently selected from C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -OR<sup>11</sup>, -C(O)R<sup>11</sup>, -C(O)OR<sup>11</sup>, -NR<sup>12</sup>C(O)OR<sup>11</sup>, -OC(O)R<sup>11</sup>, -NR<sup>12</sup>SO<sub>2</sub>R<sup>11</sup>, -SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, -NR<sup>12</sup>C(O)R<sup>11</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, -NR<sup>11</sup>R<sup>12</sup>, -S(O)<sub>j</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl) wherein j is an integer ranging from 0 to 2, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -SO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -S(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -O(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl) and -(CH<sub>2</sub>)<sub>m</sub>(4-10 membered heterocyclic), wherein m is an integer ranging from 0 to 4; said C<sub>1</sub>-C<sub>10</sub> alkyl group optionally contains 1 or 2 hetero moieties selected from O, S and -N(R<sup>12</sup>)- with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said aryl and heterocyclic R<sup>10</sup> groups are optionally fused to a C<sub>6</sub>-C<sub>10</sub> aryl group, a C<sub>5</sub>-C<sub>8</sub> saturated

cyclic group, or a 4-10 membered heterocyclic group; and said alkyl, aryl and heterocyclic R<sup>10</sup> groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -NR<sup>12</sup>SO<sub>2</sub>R<sup>11</sup>, -SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, -C(O)R<sup>11</sup>, -C(O)OR<sup>11</sup>, -OC(O)R<sup>11</sup>, -NR<sup>12</sup>C(O)R<sup>11</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, -NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, -OR<sup>11</sup> and the substituents listed in the definition of R<sup>11</sup>; each R<sup>11</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CH<sub>2</sub>)<sub>m</sub>(4-10 membered heterocyclic), wherein m is an integer ranging from 0 to 4; said alkyl group optionally includes 1 or 2 hetero moieties selected from O, S and -N(R<sup>12</sup>)-, with the proviso that two O atoms, two S atoms, or an O and S atom are not attached directly to each other; said aryl and heterocyclic R<sup>11</sup> groups are optionally fused to a C<sub>6</sub>-C<sub>10</sub> aryl group, a C<sub>5</sub>-C<sub>8</sub> saturated cyclic group, or a 4-10 membered heterocyclic group; and the foregoing R<sup>11</sup> substituents, except H, are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -C(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -CO(O)R<sup>12</sup>, -NR<sup>12</sup>C(O)R<sup>13</sup>, -C(O)NR<sup>12</sup>R<sup>13</sup>, -NR<sup>12</sup>R<sup>13</sup>, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy; and, each R<sup>12</sup> and R<sup>13</sup> is independently H or C<sub>1</sub>-C<sub>6</sub> alkyl; or

(e) a compound of the formula



or a pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

a is 0 or 1, wherein when a is 0, X may form an optional double bond with the carbon adjacent to V;

V is CHR<sup>10</sup> wherein R<sup>10</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

T is nitrogen or CH;

X is nitrogen or CR<sup>11</sup> wherein R<sup>11</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy or cyano;

Y and Z are each independently nitrogen or CR<sup>12</sup> wherein R<sup>12</sup> is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or (C<sub>1</sub>-C<sub>6</sub>)alkyl;


R<sup>1</sup> is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>2</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and

R<sup>5</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, trifluoromethyl, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkyl or R<sup>13</sup>CO- wherein R<sup>13</sup> is amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl;

or when a is 1, R<sup>1</sup> and R<sup>10</sup> may be taken together with the carbons to which they are attached to form a compound of the formula



wherein the broken lines represent optional bonds;

T, X, Y, Z, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> are defined as above;

b is 0 or 1; and


A and B are each independently CH, CH<sub>2</sub>, oxygen, sulfur, NH or nitrogen;

with the proviso that when X is nitrogen, the optional double bond between X and V does not exist;

with the proviso that when b is 0, the optional double bond between A and B does not exist; and

with the proviso that when b is 1, A and B cannot both be oxygen or sulfur; or

(f) a compound of the formula



wherein a is oxygen, CH<sub>2</sub>, C(CH<sub>3</sub>)<sub>2</sub>, NR<sup>10</sup>, sulfur, SO or SO<sub>2</sub>;

b is oxygen, CH<sub>2</sub>, C=O, C=NR<sup>11</sup>, C=NOH, SO<sub>2</sub>, Sulfur, SO, C=NO(C<sub>1</sub>-C<sub>5</sub>)alkyl or CR<sup>7</sup>R<sup>8</sup>;

each of R<sup>1</sup> through R<sup>8</sup> is selected, independently, from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), trifluoromethyl, cyano and hydroxy, or R<sup>7</sup> and R<sup>8</sup> together can be C(=O)NH<sub>2</sub> or C(=O)N(C<sub>1</sub>-C<sub>4</sub>)alkyl, with the proviso that neither R<sup>7</sup> nor R<sup>8</sup> can be halo when a is oxygen, NR<sup>11</sup>, sulfur, SO or SO<sub>2</sub>; and each of R<sup>10</sup> and R<sup>11</sup> is selected, independently, from hydrogen, benzyl and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder.

2. The use of claim 1, wherein the novelty-seeking disorder is selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

3. The use of claim 1, wherein the compound is selected from:

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(5-fluoropyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(3,4-difluorophenoxy)-methyl-2-(5-fluoropyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(5-chloropyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine;

2-(5-fluoropyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2a]-pyrazin-7-ylmethyl]-3H-benzoxazol-2-one hydrochloride;

3-[(7R,9aS)-2-(5-chloropyridin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-ylmethyl]-3H-benzoxazol-2-one; and

((7S,9aS)-7-(3-cyanophenoxy)methyl-2-(5-fluoropyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine.

4. The use of claim 1, wherein the compound is selected from:

1-[3-(4-pyridin-2-yl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one;

1-[3-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;

1-[3-[4-(5-chloro-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;

1-[3-[4-(5-bromo-pyridin-2-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one;

1-[3-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; and

1-[3-[4-(6-chloro-pyridazin-3-yl)-piperazin-1-yl]-propyl]-1,3-dihydro-benzoimidazol-2-one.

5. The use of claim 1, wherein the compound is selected from:

1-Benzoimidazol-1-yl-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-(5-Chloro-benzoimidazol-1-yl)-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-{3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl}-5-trifluoromethyl-1H-benzoimidazole;  
 1-{3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl}-1H-benzoimidazole;  
 1-{3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl}-3-methyl-1,3-dihydro-benzoimidazol-2-one;  
 1-Benzoimidazol-1-yl-3-(4-o-tolyl-piperazine-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-m-tolyl-piperazine-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-p-tolyl-piperazin-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(4-chloro-phenyl)-phenyl-methyl]-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(2-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(4-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3-chloro-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-pyrimidin-2-yl-piperazin-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-naphthalen-1-yl-piperazin-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-benzyl-piperazin-1-yl)-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(2-trifluoromethyl-benzyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-[4-(2-ethoxy-benzyl)-piperazin-1-yl]-propan-2-ol;  
 1-Benzoimidazol-1-yl-3-(4-{3-(3-trifluoromethyl-phenyl)-propyl}-piperazin-1-yl)-propan-2-ol; and  
 1-Benzoimidazol-1-yl-3-[4-[2-(3-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl]-propan-2-ol.

6. The use of claim 1, wherein the compound is selected from:

(2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-hexahydropentalene-2'-one;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2'-phenyl-octahydropentalen-2'-ol, maleate salt;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-hexahydropentalene-2-one, ethylene ket-  
 al;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-hexahydropentalene-2-one;  
 (2' $\alpha$ ,3'a $\beta$ , 5' $\alpha$ , 6'a $\beta$ )-2-Fluoro-4-[4-(5'-hydroxy-5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzoni-  
 trile, maleate salt;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5-Hydroxy-5-phenyl-hexahydro-pentalen-2-one;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-2'-phenyl-octahydro-pentalen-2'-ol, maleate salt;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-[4-(4-Fluoro-1-pyrimidyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'-ol,  
 maleate salt;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-  
 2'-ol, maleate salt;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-2'-(4-fluoro-phenyl)-octahydro-pentalen-2'-ol,  
 maleate salt;  
 (2' $\alpha$ , 3'a $\beta$ , 6'a $\beta$ )-1-(4-Fluoro-phenyl)-4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazine dihy-  
 drochloride;  
 (2' $\alpha$ , 3'a $\beta$ , 6'a $\beta$ )-5-Fluoro-2-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimi-  
 dine maleate;  
 (2' $\alpha$ ,3'a $\beta$ ,6'a $\beta$ )-2-Fluoro-4-[4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazin-1-yl]-benzoni-  
 trile, maleate;  
 (2' $\alpha$ , 3'a $\beta$ , 6'a $\beta$ )-2-Fluoro-4-[4-[5-(2-methoxy-phenyl)-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl]-piperazin-  
 1-yl]-benzonitrile, maleate;  
 (2' $\alpha$ , 3'a $\beta$ , 6'a $\beta$ )-1-Phenyl-4-(5'-phenyl-1',2',3',3'a,4',6'a-hexahydro-pentalen-2'-yl)-piperazine, dimaleate;  
 (2' $\alpha$ , 3'a $\beta$ , 5' $\alpha$ , 6'a $\beta$ )-1-(4-Fluoro-phenyl)-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine, dihydrochloride;  
 (2' $\alpha$ , 3'a $\beta$ , 5' $\alpha$ , 6'a $\beta$ )-5-Fluoro-2-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-pyrimidine, maleate;  
 (2' $\alpha$ , 3'a $\beta$ , 5' $\alpha$ , 6'a $\beta$ )-2-Fluoro-4-[4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazin-1-yl]-benzonitrile, maleate;  
 (2' $\alpha$ , 3'a $\beta$ , 5' $\alpha$ , 6'a $\beta$ )-1-Phenyl-4-(5'-phenyl-octahydro-pentalen-2'-yl)-piperazine, maleate;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-Hydroxy-5'-(2-trifluoromethyl-phenyl)-hexahydro-pentalen-2'-one;  
 (2' $\alpha$ ,3'a $\beta$ ,6'a $\beta$ )-5'-(2-trifluoromethyl-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2'-one, ethylene ketal;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-(2-Trifluoromethyl-phenyl)-hexahydro-1H-pentalen-2'-one, ethylene ketal;  
 (2' $\alpha$ ,3'a $\beta$ ,5' $\alpha$ ,6'a $\beta$ )-5'-(2-Trifluoromethyl-phenyl)-hexahydro-1H-pentalen-2'-one;



(2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(2-trifluoromethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;  
 5 (2'α, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-{4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-pyrimidine, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(3-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(4-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;  
 10 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl}-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-{4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl}-pyrimidine, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-5-Chloro-2-{4-[5'-(2-methoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-pyrimidine, maleate;  
 15 (2'α, 3'aβ, 5'α, 6'aβ)-5-Chloro-2-{4-(5'-o-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl}-pyrimidine, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(2-methanesulfonyl-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-1-Phenyl-4-[5'-(3-pyrrolidin-1-ylmethyl-phenyl)-octahydro-pentalen-2'-yl]-piperazine, dimaleate;  
 20 5-Trimethylstannayl-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, ethylene ketal;  
 5-(2-Cyano-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Cyano-4-{4-[5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(2-trifluoromethoxy-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;  
 25 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-[5'-(2-fluoro-phenyl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-(5'-pyridin-2-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl}-benzonitrile, dihydrochloride;  
 30 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-(5'-m-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl}-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-(5'-p-tolyl-octahydro-pentalen-2'-yl)-piperazin-1-yl}-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-N-(2-{5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-phenyl)-acetamide, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-N-(2-{5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-phenyl)-acetamide, maleate;  
 35 5-(2-Cyano-phenyl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, ethylene ketal;  
 2-(5-Oxo-octahydro-pentalen-2-yl)-benzamide, ethylene ketal;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-{5'-[4-(4-Cyano-3-fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl}-benzamide, maleate;  
 40 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-2-Fluoro-4-{4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-{4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-piperazin-1-yl]-pyrimidine;  
 45 (2'β, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-{4-(3', 3'a, 4', 5', 6', 6'a-hexahydrospiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-piperazin-1-yl]-pyrimidine;  
 (2'α, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-{4-(3', 3'a, 4', 5', 6', 6'a-hexahydro-3'a,6'a-dimethylspiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine, maleate;  
 50 (2'β, 3'aβ, 5'α, 6'aβ)-5-Fluoro-2-{4-(3', 3'a, 4', 5', 6', 6'a-hexahydro-3'a,6'a-dimethylspiro[isobenzofuran-1(3H),2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-pyrimidine, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-{4-(3', 3'a, 4', 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-2-Fluoro-4-{4-(3', 3'a, 4', 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 55 (2'α, 3'aβ, 5'α, 6'aβ)-1-Phenyl-4-(3', 3'a, 4', 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pentalen]-5'-yl)-5'-yl)-piperazine, maleate;  
 (2'β, 3'aβ, 5'α, 6'aβ)-1-Phenyl-4-(3', 3'a, 4', 4', 5', 6', 6'a-hexahydrospiro[2H-1-benzopyran-2,2'(1'H)-pen-

talen]-5'-yl]-5'-yl)-piperazine, maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(3, 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'  
 (1'H)-pentalen]-5'-yl]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 (2'β, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-(3, 3', 3'a, 4, 4', 5', 6', 6'a-hexahydrospiro[2H-6-fluoro-1-benzopyran-2,2'  
 (1'H)-pentalen]-5'-yl]-5'-yl)-1-piperazinyl]-benzonitrile, maleate;  
 (2α,3aβ,5α,6aβ)-5-Benzylamino-hexahdropentalen-2-one, mono -ethylene ketal;  
 (2α,3aβ,5α,6aβ)-5-Amino-hexahdropentalen-2-one, mono -ethylene ketal;  
 (2α,3aβ,5α,6aβ)-5-(5-Fluoro-2-nitro-phenylamino)-hexahdropentalen-2-one, mono -ethylene ketal;  
 (2α,3aβ,5α,6aβ)-5-(2-Amino-5-fluoro-phenylamino)-hexahdropentalen-2-one, mono -ethylene ketal;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-[5'-(6-fluoro-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-octahydro-pentalen-2'-  
 yl]-piperazin-1-yl]-benzonitrile, dimesylate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-[5'-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-octahydro-pentalen-2'-yl]-pip-  
 erazin-1-yl]-benzonitrile, mesylate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-1-[5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-1,3-dihydro-  
 benzoimidazol-2-one, mesylate;  
 (2α,3aβ,5α,6aβ)-5-(6-Fluoro-2-methyl-benzoimidazol-1-yl)-hexahydro-pentalen-2-one;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-[5'-(6-fluoro-2-methylbenzoimidazol-1-yl)-octahydro-pentalen-2'-yl]-piper-  
 azin-1-yl]-benzonitrile, dimesylate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-6-Fluoro-2-methyl-1-[5'-(4-phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-benzoim-  
 idazole, dimaleate;  
 (2α,3aβ,6aβ)-5-(1H-Indol-3-yl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one, mono-ethylene ketal;  
 (2'α, 3'aβ, 5'α, 6'aβ)-2-Fluoro-4-[4-[5'-(1H-indol-3-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzonitrile,  
 maleate;  
 (2'α, 3'aβ, 5'α, 6'aβ)-3-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-indole, maleate;  
 (2α,3aβ,6aβ)-5-(4-Fluoro-phenoxy)-hexahydro-pentalen-2-one;  
 (2'α, 3'aβ, 5'β, 6'aβ)-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-2-Fluoro-4-[4-[5'-(4-fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-benzoni-  
 trile, maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-5-Fluoro-2-[4-[5'-(4-fluoro-phenoxy)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-pyrimidine,  
 maleate;  
 (2'β, 3'aβ, 5'β, 6'aβ)-1-[5'-(4-Fluoro-phenoxy)-octahydro-pentalen-2'-yl]-4-phenyl-piperazine, maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione maleate;  
 (2'α,3'aβ,5'α,6'aβ)-5-Hydroxy-hexahydro-pentalen-2-one, ethylene ketal;  
 (2'α,3'aβ,5'α,6'aβ)-2-Oxo-3-(5-oxo-octahydro-pentalen-2-yl)-2,3-dihydro-benzoimidazole-1-carboxylic acid  
 tert-butyl ester, ethylene ketal;  
 (2'α,3'aβ,5'α,6'aβ)-2-(5-oxo-octahydro-pentalen-2-yloxy)-3H-benzoimidazole-1-carboxylic acid tert-butyl es-  
 ter, ethylene ketal;  
 (2'β, 3'aβ, 5'α, 6'aβ)-3-[5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-2-oxo-2,3-dihydro-  
 benzoimidazole-1-carboxylic acid tert-butyl ester;  
 (2'β, 3'aβ, 5'α, 6'aβ)-1-[5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-1,3-dihydro-ben-  
 zoimidazol-2-one, maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-2-Fluoro-4-[4-[5'-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-octahydro-pentalen-2'-yl]-pip-  
 erazin-1-yl]-benzonitrile, maleate;  
 (2'β, 3'aβ, 5'α, 6'aβ)-1-[5'-[4-(3,4-Difluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-1,3-dihydro-ben-  
 zoimidazol-2-one, maleate;  
 (2'β, 3'aβ, 5'α, 6'aβ)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-1H-benzoimidazole,  
 maleate;  
 (2'α,3'aβ,5'α,6'aβ)-2-(5-Oxo-octahydro-pentalen-2-yl)-isoindole-1,3-dione;  
 (2'α, 3'aβ, 5'β, 6'aβ)-2-[5'-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2'-yl]-isoindole-1,3-dione, maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-4-[4-[5'-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-octahydro-pentalen-2'-yl]-piperazin-1-yl]-  
 2-fluoro-benzonitrile, maleate;  
 (2'α, 3'aβ, 5'β, 6'aβ)-2-[5'-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-isoindole-  
 1,3-dione, maleate;  
 (2'β, 3'aβ, 5'α, 6'aβ)-2-[5'-[4-(3,4-Difluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-isoindole-1,3-di-  
 one, maleate;  
 (2'β, 3'aβ, 5'α, 6'aβ)-2-[5'-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-octahydro-pentalen-2'-yl]-isoindole-1,3-dione,  
 maleate; and  
 (2'β, 3'aβ, 5'α, 6'aβ)-N-[5-(4-Phenyl-piperazin-1-yl)-octahydro-pentalen-2-yl]-benzamide, maleate.

7. The use of claim 1, wherein the compound is selected from:

2-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;  
5-Fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-1H-indole;  
5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;  
5-Fluoro-2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-indole;  
5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;  
2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole;  
5-Fluoro-2-(4-[5'-fluoro]pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;  
2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole;  
5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-azaindole; and  
2-[4-(4-fluoro-phenyl)-piperazin-1-ylmethyl]-1H-azaindole.

8. The use of a dopamine D4 receptor ligand in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder.


9. The use of claim 8 wherein the novelty-seeking disorder is selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

10. A compound, as defined in any one of claims 1 or 3 to 7 for use in the treatment or prevention of a novelty-seeking disorder.

11. A dopamine D4 receptor ligand for use in the treatment or prevention of a novelty-seeking disorder.

12. A compound as claimed in claim 10 or claim 11 wherein the novelty-seeking disorder is selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

**THIS PAGE BLANK (USPTO)**



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 177 792 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
**23.10.2002 Bulletin 2002/43**

(51) Int Cl.7: **A61K 31/505, A61P 25/30,  
A61P 25/32, A61P 43/00**

(43) Date of publication A2:  
**06.02.2002 Bulletin 2002/06**

(21) Application number: **01306163.5**

(22) Date of filing: **18.07.2001**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **27.07.2000 US 221268 P**

(71) Applicant: **Pfizer Products Inc.  
Groton, Connecticut 06340 (US)**

(72) Inventors:  
• **Fliri, Anton Franz Josef  
Groton, Connecticut 06340 (US)**

• **Sanner, Mark Allen  
Groton, Connecticut 06340 (US)**  
• **Seymour, Patricia Ann  
Groton, Connecticut 06340 (US)**  
• **Zorn, Stevin Howard  
Groton, Connecticut 06340 (US)**

(74) Representative: **Ruddock, Keith Stephen et al  
Pfizer Limited,  
European Patent Department,  
Ramsgate Road  
Sandwich, Kent CT13 9NJ (GB)**

(54) **Dopamine D4 Ligands for the treatment of novelty-seeking disorders**

(57) The use of a dopamine D4 receptor ligand in the manufacture of a medicament for the treatment or prevention of a novelty-seeking disorder, particularly pathological gambling, attention deficit disorder with hy-

peractivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction.

EP 1 177 792 A3



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

Application Number

EP 01 30 6163

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,X	US 5 852 031 A (SANNER MARK A ET AL) 22 December 1998 (1998-12-22) * abstract * * column 1, line 27 - line 31 * * column 7, line 37-41 * * column 9, line 15 - line 17 * * claims 1-17 *	2-7,9, 10,12	A61K31/505 A61P25/30 A61P25/32 A61P43/00
X	WO 96 10571 A (PFIZER ;DESAI KISHOR A (US); FLIRI ANTON F J (US); SANNER MARK A ( ) 11 April 1996 (1996-04-11) * abstract * * page 1, line 8 - line 12 * * page 2, line 12 - line 17 * * page 14, line 19 - line 21 * * claims 1-32 * --- -/--	2-7,9, 10,12	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search: see sheet C</p>			
Place of search MUNICH		Date of completion of the search 28 August 2002	Examiner Taylor, G.M.
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.92 (P04007)



European Patent  
Office

**INCOMPLETE SEARCH  
SHEET C**

Application Number  
EP 01 30 6163

Claim(s) searched incompletely:  
2-7,9,10,12

Claim(s) not searched:  
1,8,11

Reason for the limitation of the search:

Present claims 1, 8 and 11 refer to the treatment of "novelty-seeking disorders". Since this term does not appear to have accepted definition in the art, the scope of protection sought is vague and indefinite. The indications searched have therefore been restricted to those given in claims 2, 9 and 12.

Moreover, present claims 1, 8 and 11 relate to an extremely large number of possible compounds. Support within the meaning of Art. 84 EPC and/or disclosure within the meaning of Art. 83 EPC is to be found, however, for only a very small proportion of the compounds, namely those explicitly named in claims 3-7.

Moreover, the application does not contain one single example - either in vivo or in vitro - of the use of a dopamine D4 receptor ligand in the treatment of any indication claimed.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds as defined in claims 3-7 for the treatment of the indications given in claim 2.



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 01 30 6163

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 96 04250 A (PFIZER ; FARACI WILLIAM S (US); FLIRI ANTON F J (US); NEILL BRIAN T) 15 February 1996 (1996-02-15) * abstract * * page 1, line 10 - line 17 * * page 2, line 11 - page 4, line 8 * * page 10, line 9 - page 12, line 10 * * claims 1-16 *	2-7,9, 10,12	
X	WO 95 34555 A (FLIRI ANTON F ; SANNER MARK A (US); ZORN STEVIN H (US); NEILL BRIAN) 21 December 1995 (1995-12-21) * abstract * * page 1, line 6 - line 17 * * page 1, line 34 - page 2, line 26 * * page 5, line 3 - line 19 * * claims 1-14 *	2-7,9, 10,12	TECHNICAL FIELD8 SEARCHED (Int.Cl.7)
X,D	WO 96 25414 A (UPJOHN CO ; TENBRINK RUTH E (US)) 22 August 1996 (1996-08-22) * abstract * * page 1, line 4 - line 6 * * page 4, line 10 - page 10, line 25 * * page 10, line 33 * * page 11, line 13 - line 14 * * claims 1-15 *	2-7,9, 10,12	
X	SANNER M A ET AL: "Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 7, 7 April 1998 (1998-04-07), pages 725-730, XP004136954 ISSN: 0960-894X * the whole document *	10,12	
	--- -/-		

EPO FORM 1503 03.02 (P04C10)





European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 01 30 6163

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D,X	WO 98 08835 A (BUTLER TODD WILLIAM ; PFIZER (US); FLIRI ANTON FRANZ JOSEPH (US)) 5 March 1998 (1998-03-05) * abstract * * page 1, line 7 - line 14 * * page 2, line 16 - page 3, line 10 * * page 3, line 27 - page 5, line 27 * * claims 1-16 *	10,12	
P,X	EP 1 074 257 A (PFIZER PROD INC) 7 February 2001 (2001-02-07) * abstract * * page 3, line 34 - page 4, line 10 * * claims 1-10 *	2-7,9, 10,12	
P,X	WO 00 76981 A (NEUROGEN CORP ; ZHAO HE (US); THURKAUF ANDREW (US)) 21 December 2000 (2000-12-21) * abstract * * page 3, line 2 - line 10 * * claims 1-47 *	12	TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EP0 FORM 1800 (3.92) (P4C10)

# ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 01 30 6163

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-08-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5852031	A	22-12-1998	AT 209648 T	15-12-2001
			AU 681310 B2	21-08-1997
			AU 3189395 A	26-04-1996
			DE 69524241 D1	10-01-2002
			DE 69524241 T2	13-06-2002
			DK 783503 T3	11-02-2002
			EP 0783503 A1	16-07-1997
			FI 971310 A	27-03-1997
			JP 9511527 T	18-11-1997
			JP 3287574 B2	04-06-2002
			KR 244848 B1	02-03-2000
			NO 971416 A	20-05-1997
			NZ 290936 A	26-01-1998
			PL 319636 A1	18-08-1997
			SI 9520096 A	30-04-1998
			SK 32597 A3	09-09-1998
			BR 9504230 A	06-08-1996
			CA 2200959 A1	11-04-1996
			CN 1168672 A ,B	24-12-1997
			CZ 9700947 A3	15-07-1998
			ES 2166830 T3	01-05-2002
			HR 950507 A1	31-08-1997
			HU 77354 A2	30-03-1998
			WO 9610571 A1	11-04-1996
			IL 115384 A	28-10-1999
			PT 783503 T	28-03-2002
			RU 2163239 C2	20-02-2001
			TR 960273 A2	21-06-1996
			TW 406081 B	21-09-2000
			ZA 9508223 A	01-04-1997
WO 9610571	A	11-04-1996	AT 209648 T	15-12-2001
			AU 681310 B2	21-08-1997
			AU 3189395 A	26-04-1996
			BR 9504230 A	06-08-1996
			CA 2200959 A1	11-04-1996
			CN 1168672 A ,B	24-12-1997
			CZ 9700947 A3	15-07-1998
			DE 69524241 D1	10-01-2002
			DE 69524241 T2	13-06-2002
			DK 783503 T3	11-02-2002
			EP 0783503 A1	16-07-1997
			ES 2166830 T3	01-05-2002
			FI 971310 A	27-03-1997
			HR 950507 A1	31-08-1997
			HU 77354 A2	30-03-1998

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 6163

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-08-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9610571	A		WO 9610571 A1	11-04-1996
			IL 115384 A	28-10-1999
			JP 9511527 T	18-11-1997
			JP 3287574 B2	04-06-2002
			KR 244848 B1	02-03-2000
			NO 971416 A	20-05-1997
			NZ 290936 A	26-01-1998
			PL 319636 A1	18-08-1997
			PT 783503 T	28-03-2002
			RU 2163239 C2	20-02-2001
			SI 9520096 A	30-04-1998
			SK 32597 A3	09-09-1998
			TR 960273 A2	21-06-1996
			TW 406081 B	21-09-2000
			US 5852031 A	22-12-1998
			ZA 9508223 A	01-04-1997
WO 9604250	A	15-02-1996	AU 703431 B2	25-03-1999
			AU 2351095 A	04-03-1996
			BR 9503572 A	30-04-1996
			CA 2196769 A1	15-02-1996
			EP 0775118 A1	28-05-1997
			FI 970469 A	04-04-1997
			WO 9604250 A1	15-02-1996
			JP 3004727 B2	31-01-2000
			JP 9510706 T	28-10-1997
			NZ 284851 A	28-07-1998
			TR 960450 A2	21-07-1996
			NO 970498 A	04-02-1997
WO 9534555	A	21-12-1995	AT 206708 T	15-10-2001
			CA 2192975 A1	21-12-1995
			DE 69523155 D1	15-11-2001
			DE 69523155 T2	07-02-2002
			DK 765320 T3	26-11-2001
			EP 0765320 A1	02-04-1997
			ES 2163506 T3	01-02-2002
			FI 965021 A	13-12-1996
			WO 9534555 A1	21-12-1995
			JP 2860604 B2	24-02-1999
			JP 9506637 T	30-06-1997
			PT 765320 T	28-02-2002
WO 9625414	A	22-08-1996	AU 4859596 A	04-09-1996
			EP 0809642 A1	03-12-1997
			JP 11500123 T	06-01-1999

EPO FORM P459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 6163

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-08-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9625414	A		WO 9625414 A1	22-08-1996
			US 5912246 A	15-06-1999
WO 9808835	A	05-03-1998	AU 3632297 A	19-03-1998
			EP 0925291 A1	30-06-1999
			HR 970455 A1	31-08-1998
			WO 9808835 A1	05-03-1998
			JP 2000502360 T	29-02-2000
			JP 3152941 B2	03-04-2001
			ZA 9707597 A	25-02-1999
EP 1074257	A	07-02-2001	US 6231833 B1	15-05-2001
			AU 4897600 A	08-02-2001
			EP 1074257 A1	07-02-2001
			HU 0003118 A2	28-04-2001
			JP 2001064178 A	13-03-2001
			NZ 506154 A	01-03-2002
WO 0076981	A	21-12-2000	AU 5877500 A	02-01-2001
			WO 0076981 A1	21-12-2000

EPO FORM P4459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82